市场调查报告书
商品编码
1240034
全球基因检测市场——规模、测试、应用、技术、行业分析报告、国家展望、增长潜力、适用性、竞争市场份额和预测,2023-2032 年Genetic Testing Market Size, By Test, By Application, By Technology, Industry Analysis Report, Country Outlook, Growth Potential, Application Potential, Competitive Market Share & Forecast, 2023-2032 |
由于医生越来越多地在临床实践中采用基因检测,预计到 2032 年全球基因检测市场将经历强劲增长。
基因检测在遗传和肿瘤疾病中的广泛应用,以及医生在临床治疗中越来越多地使用基因检测,预计将在预测期内推动市场扩张。
技术发展和新测试的可用性推动了基因检测的需求,增加了患者对个性化药物的偏好并加速了公司的发展。 此外,以基因检测解决方案为重点的研发投入将在未来几年推动市场扩张。 例如,英国政府已宣布超过 1.277 亿美元用于促进新生儿罕见遗传病的诊断。 还提供了额外的资金来提高癌症检测的速度和准确性,并启动解决健康差异的计划。
基因检测市场按检测、应用、技术和区域进行细分。
根据测试,到 2032 年,预测测试部分的估值预计将超过 19 亿美元。 技术进步和遗传疾病日益流行将推动预测测试市场。 有影响力的渲染因素包括新型基因检测方法和技术的发展,以及效率和准确性的提高。 例如,无创产前检测 (NIPT) 和无细胞胎儿 DNA 检测的引入将加速基因检测的接受度并支持市场扩张。
从应用来看,随着心肌病、心律失常和高胆固醇等遗传性心血管疾病所占比例的增加,预计未来几年心血管疾病领域将显着扩大。 此外,良好的心血管疾病检测报销有望推动这一领域的增长。
在技术方面,预计分子检测领域在预测期内将显着增长。 基因分型被认为有助于预后、疾病诊断、进展、治疗选择和反应以及遗传特异性药物靶标的鑑定。
按地区划分,到 2032 年,欧洲基因检测市场预计将占据超过 98 亿美元的业务份额。 该地区的市场增长归因于专注于将先进技术融入基因检测设备的行业巨头的扩张。
Global Genetic Testing Market is set to experience robust growth through 2032 owing to the increasing adoption of genetic testing for clinical care by physicians. The growing use of genetic testing in genetic and oncology illnesses, as well as increased physician use of genetic tests in clinical treatment, is set to drive market expansion during the forecast timeframe.
The demand for genetic testing has been fueled by technological developments and the availability of new tests, which has raised patient preference for tailored medications and accelerated corporate growth. Furthermore, hefty investments in R&D studies focusing on genetic testing solutions would boost the market expansion in the coming years. Citing an instance, the government of UK announced more than USD 127.7 million to accelerate the diagnosis of rare genetic diseases in newborns. Besides, additional funding was offered to kickstart programs to improve the speed and accuracy of cancer detection and managing health inequalities.
The genetic testing market has been divided in terms of test, application, technology, and region.
Based on test, the predictive testing segment is expected to amass more than USD 1.9 billion valuation by 2032. Technological developments, combined with an increase in the prevalence of genetic illnesses, will drive the predictive testing market. High-impact rendering elements include the development of novel genetic testing methods and technologies, as well as improved efficiency and accuracy. The introduction of non-invasive prenatal testing (NIPT) or cell-free fetal DNA testing, for example, will accelerate the acceptance of genetic testing and support the market expansion.
With respect to application, the cardiovascular diseases segment is anticipated to expand significantly over the review years credited to the growing rates of inherited cardiovascular conditions including cardiomyopathy, arrhythmias, as well as high blood cholesterol. Moreover, good reimbursement provided for the detection of cardiovascular disorders is set to propel segmental growth.
In terms of technology, the molecular testing segment is poised to proliferate robustly through the forecast period. Genotyping can help with prognosis, disease diagnosis, and progression, as well as guide treatment options and response, and identify targets for gene-specific medicines.
From the regional perspective, the Europe genetic testing market is speculated to attain more than USD 9.8 billion business share by 2032. The regional market growth can be credited to the expanding presence of major players in the industry that are focusing on integrating advanced techniques within genetic testing equipment.